SUMMARY A double-blind, cross-over comparison of Naprosyn* (naproxen) 750 mg daily and Butacote* (enteric-coated phenylbutazone) 300 mg daily was carried out in a multi-centre trial. Twenty-five patients, mostly male and under 40 years of age, were entered. After a 2-week period in which any existing anti-inflammatory drugs were tailed off, patients were entered into the trial and treated for 1 month with each drug. Patients were assessed at 4-weekly intervals. Both drugs significantly reduced morning stiffness. Morning pain and discomfort and wall-tragus distance were also significantly reduced by both drugs during the trial. Results of the Schober test showed improvement during both treatment periods. There were no overall statistically significant differences between the
Since the original reports of Hart (1953) , phenylbutazone has been accepted as an effective medication for ankylosing spondylitis and its prolonged use in this condition, as reported by Mason and Howes (1963) , showed it to be a most satisfactory treatment, although there has always been some anxiety as to the possibility of blood dyscrasias developing. In 1973, Hill and Hill, in an open trial with a placebo pulse, reported on the successful use of naproxen in managing ankylosing spondylitis. They updated this report (Hill and Hill, 1976) after gathering up to 30 months' experience in some patients. Subsequently a pilot study was set up to compare Naprosyn 500 mg daily with 300 mg of Butacote daily when it was noted that Naprosyn was slightly less effective than Butacote (Mathews et al., 1975) . The present study was undertaken to compare a daily dose of 750 mg naproxen (one 250 mg tablet in the morning and 2 tablets at night) with phenylbutazone enteric-coated tablets (Butacote) 100 mg 3 times a day. Butacote was given as it had been shown to have better gastrointestinal tolerance than phenylbutazone (Rushford and Fowler, 1970 
Material and methods
The trial was a double-blind, cross-over study with double dummy technique so that the active drugs could be presented as the standard commercial preparations. It was carried out in 5 centres, all using the same protocol. Patients were admitted only if they had radiographic evidence of sacroiliitis of at least grade 2 (Atlas of Standard Radiographs of Arthritis, 1963) and if they had clinically active symptoms. The latter was determined during the run-in period when current therapy was gradually reduced so that paracetamol only was taken during the last 5 days. Following this 2 week run-in period, provided there had been a deterioration in at least 2 of the parameters measured, the patients were admitted into the trial. They were then given each preparation for 4 weeks, the order of treatment being randomised.
Patients were excluded if they were suffering from significant renal, hepatic or cardiac disease, diseases likely to be associated with sacroiliitis (eg, psoriasis), a history of untoward reaction to either drug, peptic ulcer, or if they were likely to become pregnant.
At all visits the following parameters (Table 1) were assessed: morning stiffness, immobility stiffness, For analysis patients were split into two groups: group I, Naprosyn given during the first period of treatment, and group II, Butacote given during the first period of treatment. Changes from baseline and differences between groups were calculated. A test on the pooled data was also done.
Results
Twenty-five patients were entered into the trial, of whom 23 were males. Over two-thirds were under 40 years of age and except for a few cases the duration of the disease was below 15 years ( Table 2 ). The initial findings at day 0 are given in Table 3 . For morning stiffness the 2 groups were significantly different at day 0. This was due to a significant deterioration during the run-in period in group I but not in group II. The changes from baseline during therapy are given in Table 4 . The overall views of symptoms and comparison with previous visit are given in Table 5 . In group I, all mean changes were positive compared with the previous visit and the patient's assessment on Naprosyn was statistically significant. In group It both patients' and physicians' subjective assessment showed a significant improvement during the first phase (Butacote) but a deterioration during the second phase (Naprosyn). Subjective assessment of severity of symptoms was graded lower on Butacote than on Naprosyn and the patients' subjective assessments of the differences between the effects of the 2 drugs was statistically significant (P=0.03).
The preference at the end of treatment is shown in Table 6 . Butacote was preferred more times than Naprosyn but the difference is not statistically significant. *Side effects elicited by indirect questioning were slightly more in number on Butacote (16) than on Naprosyn (13). The number of patients reporting side effects was 8 on each drug. These side effects were generallynon-specific but several patients complained of indigestion and sore mouth. One patient discontinued medication while on Butacote. Discussion Naprosyn and Butacote have both been shown to improve morning stiffness, morning pain, and walltragus distance in patients suffering from ankylosing spondylitis. Although specific measurements showed no real differences between the drugs, Butacote was favoured according to the global assessments by physicians and significantly so by patients.
As far as the 2 treatment groups are concerned, group II showed a higher number of statistically significant differences from baseline than did group I. The only difference between the groups at baseline was in the duration ofmorning stiffness. However, the duration of morning stiffness decreased significantly during treatment in both groups of patients. It may be that the order of medication in group 11, Butacote followed by Naprosyn, produced the difference.
Phenylbutazone preparations have been used for more than 25 years in the treatment of ankylosing spondylitis. It is an effective drug with a well-defined position amongst the available treatments. However, side effects, including the occasional severe blood dyscrasia, are well documented. Naprosyn is a (Cuthbert, 1974) .
It is suggested from this study that Naprosyn will have a useful place in the management of ankylosing spondylitis. We thank Dr. P Fowler of Geigy Pharmaceuticals for providing the Butacote and placebo used in this study, and Dr. P Freeman of University College London, London for carrying out the statistical analysis. 
